Company Encyclopedia
View More
name
Sanara Medtech
SMTI.US
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body.
332.33 B
SMTI.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care SuppliesIndustry
Industry Ranking23/42
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-26.46%E
    • Profit Margin-36.80%E
    • Gross Margin92.88%A
  • Growth ScoreC
    • Revenue YoY30.52%A
    • Net Profit YoY-348.29%E
    • Total Assets YoY-19.72%E
    • Net Assets YoY-84.44%E
  • Cash ScoreC
    • Cash Flow Margin-271.74%D
    • OCF YoY30.52%A
  • Operating ScoreA
    • Turnover1.28A
  • Debt ScoreE
    • Gearing Ratio91.36%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sanara MedTech to Participate in the Piper Sandler 37th Annual Healthcare Conference on December 3rd

    FORT WORTH, TX, Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- Sanara MedTech Inc. ( "Sanara," the "Company," "we," "our" or "us" ) ( Nasdaq: SMTI ) , a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare ...

    GlobeNewswire·
    US
    SMTI
    -0.50%
    GlobeNewswire·
    US
    SMTI
    -0.50%

    H.C. Wainwright Keeps Their Buy Rating on Sanara MedTech (SMTI)

    H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Sanara MedTech with a price target of $36.00. The analyst consensus on Sanara MedTech is a Moderate Buy with an average price target of $41.00.

    Tip Ranks·
    US
    SMTI
    -0.50%
    Tip Ranks·
    US
    SMTI
    -0.50%

    Sanara MedTech (NASDAQ:SMTI) Announces Earnings Results

    Sanara MedTech announced quarterly earnings of $0.09 per share, surpassing analyst expectations of ($0.24). Despite a negative net margin of 10.22% and return on equity of 26.43%, the stock fell $6.66 to $21.38. Institutional investors adjusted holdings, with Lazard Asset Management increasing shares significantly. Analysts have mixed ratings, with a consensus 'Hold' and an average price target of $50.00. Sanara MedTech develops surgical and wound care products in the U.S.

    Market Beat·
    US
    SMTI
    -0.50%
    Market Beat·
    US
    SMTI
    -0.50%

    Sanara Medtech | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 26.33 M

    LB filings·
    US
    SMTI
    -0.50%
    LB filings·
    US
    SMTI
    -0.50%

    Medical tech firm Sanara's Q3 revenue misses estimates after Tissue Health Plus unit closure

    Sanara Medtech's Q3 revenue rose 22% year-over-year to $26.3 million, falling short of analyst expectations of $26.6 million. The company reported a net income of $0.8 million from continuing operations, an improvement from last year's loss. Sanara has ceased operations of its Tissue Health Plus unit to focus on its core surgical business. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $50.00, representing a potential upside of 43.9% from its recent closing price of $28.04.

    Reuters·
    US
    SMTI
    -0.50%
    Reuters·
    US
    SMTI
    -0.50%
    © 2025 Longbridge｜Disclaimer